Satya Nadella is the CEO of Microsoft
Stephen Brashear/Getty ImagesMicrosoft operates in 170 countries and is one of the best places to work in 2020, according to the company review site Glassdoor.
But getting a job at Microsoft is more complicated now. The tech giant has paused hiring for some roles and moved its summer internship online.
We spoke to Microsoft's current and former employees, including a former executive staffing leader, to find out ways you can stand out as a candidate right now.
Visit Business Insider's homepage for more stories.
Microsoft's job vacancies and internships may be different during the COVID-19 pandemic, but the path to landing a job there looks much the same, according to current and former employees.
Business Insider spoke to a newbie at the tech giant and former employees in Europe about what a candidate needs to get hired.
While the whole process is now quicker and virtual, recruiters are still looking for the same traits in candidates: Someone confident in telling their original story beyond the CV, and a clear reason for choosing Microsoft over other companies.
The tech giant operates in more than 170 countries, counting more than 144,000 employees worldwide. It is also one of the best places to work for in 2020 both in the UK and the US, according to the company review site Glassdoor.
Microsoft is known for its rigorous hiring process — made up of at least four interviews — testing candidates first on knowledge and then on behavioral traits and culture fit.
Each candidate is screened by recruiters, their potential boss, and the wider team they will work with.
Competition is higher than usual as the economic crisis has left many people jobless, and back in April Microsoft announced pausing hiring for some roles due to uncertainty caused by the coronavirus crisis.
Here's what you need to get hired at Microsoft right now.
Deborah Harding is Microsoft's former executive recruiter leader for Central and Eastern Europe and now EMEA director for recruitment at the software company Pivotal.
Write a succinct one-page CV stating your most relevant experiences — and stand out
Be memorable, said Microsoft's former executive recruiter leader for Central and Eastern Europe Deborah Harding.
"In my team, we were really interested in the short bio at the beginning of the CV," she said. A candidate once wrote in the bio "I get s**t done" proving Harding's team that she was good at executing and delivering tasks.
"I never forget it, someone who actually swears on a CV is a bit like 'wow', but we bought her in straight away because that's what they [Microsoft's recruiters] are looking for: People who are a little bit different, honest, collaborative, creative, and think outside the box," Harding said.
Soft skills are also important.
You can teach someone else to do something, but soft skills are the ones big tech corporations look for — and it's harder to be trained on those, she added.
When it comes to writing to the body of your résumé, include only your most relevant experiences. Don't give lots of detail about previous roles just because you enjoyed them, said Zach Jones, a Microsoft support engineer hired in September. In Jones' case, he got rid of his trucking experience, which didn't demonstrate any of the skills Microsoft sought.
But don't feel discouraged if you haven't got the right qualifications, apply anyway, he said. Recruiters look for passionate candidates who can prove their excitement for the subject. So if you make apps from scratch or build robots in your shed on weekends, write it on your resume.
Jones, for example, started programming while working full-time as a motor transport operator in the US Marine Corps as he wanted to learn how to make games — his true passion. He taught himself how to code and then applied to Coding Dojo, an educational company providing programming boot camps, which proved his passion and devotion for the subject.
"My CV isn't impressive. I don't have a college degree in this [support engineering], and that's okay, that's not necessarily what they [Microsoft's recruiters] are looking for," Jones said.
Microsoft makes resources available online — use them
Charul Pant is an MBA candidate at the London Business School and Microsoft's former project manager
Before applying for a role, understand what Microsoft looks for. On its website, Microsoft has tips on how to best prepare for interviews, with a specific section on how to get ready for a virtual process, as well as a detailed description of its values, which include traits like being customer-obsessed, open-minded, and thinking big.
But don't limit yourself to its website, dig further online. Watch Microsoft's series of developer conferences and take notes, said Charul Pant, former project manager at Microsoft and now an MBA candidate at London Business School.
"They [candidates] will get an understanding of what's going on in Microsoft, what are its future plans, what didn't go well, how they are preparing for COVID, etc…," she said.
She added: "Having a good understanding of Microsoft's product line and the competitors is very important … I would also advise people depending upon how much time they have to prepare for an interview to go deeper and understand how [Microsoft's CEO] Satya Nadella brought through a cultural change in Microsoft."
Review academic studies and technical knowledge specific to your role
Zach Jones is a support engineer at Microsoft
Normally applicants can apply for roles on Microsoft's website with a CV (usually a cover letter isn't required, but former and current employees suggest uploading it anyway), and, depending on the role, they are also advised to upload a portfolio. The next step is a screening in which a recruiter checks that an applicant's profile fits with the role.
Then it gets to the real part: recruiters test candidates on practical knowledge. While interviewing for Microsoft's support engineering role, Jones was asked questions on how to trace information and how it is transferred from front-end to back-end — mostly technical knowledge that he would have required in the job.
For the final round, you'd be interviewed by the hiring manager, who will check culture fit and behavioral traits. A former senior hiring manager who preferred to stay anonymous said candidates were often tested through a written exercise, which required them to answer a question about the sector they were applying for.
For example, in the case of startups the question would have been: How would you identify the best startups in your ecosystem, and why? Do you have recommendations?
"It [the written test] is always a good indicator: Some would have spelling mistakes ... Others would have a perfect match, beyond impeccable presentation, and it gives a lot about how a person operates ... It was a blend of both thinking, curiosity, as well as how do they [candidates] actually present their ideas," the source said.
But the source added: "I don't think there's any rocket science to Microsoft's questions, really, giving your heart and mind during the process would make you stand out."
Prove your interest and curiosity by asking these questions
Don't be afraid to ask questions at the end of the interview, "it just shows that you've genuinely thought about the role and you're curious about it," the same source said.
Ask the interviewer questions such as "How do you define success for this role"; "How do you see us working together as a team"; and if it's a manager you're talking to, ask about their management style, the source said.
Microsoft's Zach Jones said he asked about scenarios his potential team would have faced, and added: "I always recommend asking about [culture] fit, if you don't feel like you belong somewhere, you're gonna have a rough time especially right now when everything is over the computer."
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea” or the "Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has signed a binding memorandum of understanding ("MOU”) with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division ("Jubilant”). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement ("ELDA”) for Navidea’s Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America.
In connection with the MOU, Jubilant made a $1 million equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed. The investment was priced "at the market”, which was the closing price of Navidea’s common stock on the NYSE American immediately preceding the investment.
The MOU outlines certain terms that are expected to be included in the ELDA, including:
Jubilant to provide Navidea with an additional $19 million in the form of stock purchases and license fees, subject to the achievement of certain milestones, to be used to fund Navidea’s upcoming NAV3-32 (Phase 2B) and NAV3-33 (Phase 3) trials.
Jubilant will pay license fees and sales-based royalties to Navidea based on revenue generated from the sale of Navidea’s Rheumatoid Arthritis Diagnostic in the licensed territory.
Jubilant will serve as the exclusive commercial and distribution partner for Navidea’s Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America. Jubilant will be responsible for all commercialization efforts within the licensed territory.
The execution of the ELDA is subject to certain conditions, including Jubilant’s completion of due diligence.
Navidea also announced that on August 9, 2020, it signed a binding commitment letter with Mastiff Group LLC, for a private placement financing of up to $25 million in aggregate gross proceeds of shares of Navidea's common stock. Shares will be priced either "at the market” or at a premium to Navidea’s closing price on the date of execution (the "Private Placement Financing”). Navidea expects to sign definitive documents for a common stock only transaction, with an investor syndicate comprised of Mastiff Group LLC, John Kim Scott, Jr. and other fundamental biotech focused investors no later than August 18, 2020, with the closing to take place within 15 business days thereafter. The closing will be subject to the approval by the NYSE American of the Company’s additional listing application and other customary closing conditions.
"We're excited about the prospect of this partnership with Jubilant and the support of our investors through the committed financing" said Jed Latkin, CEO of Navidea. "The combination of Jubilant’s large nuclear medicine footprint and commitment to expand its penetration in the radio-diagnostics market makes them the ideal partner for our Rheumatoid Arthritis diagnostic. Execution of the ELDA will be a monumental step for our company, and we are pleased to have a strengthened balance sheet as we move forward.”
The securities to be sold in the private placement have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Navidea's securities. No offer, solicitation or sale will be made in any state or other jurisdiction in which such offering, solicitation or sale would be unlawful.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
About Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division.
Jubilant Radiopharma is an industry leading pharmaceutical company specializing in Nuclear Medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of IMPROVING LIVES THROUGH NUCLEAR MEDICINE™ on a global scale. Nearly a thousand strong and growing, the business consists of two distinct divisions; The Radiopharmaceuticals Division and the Radiopharmacies Division. Jubilant’s (JUBILANT:NSE) Radiopharmaceuticals Division has a solid foundation in developing, manufacturing and commercializing radiopharmaceuticals used for the diagnosis and treatment of various diseases. Jubilant continuously invests in the development of generic and new novel diagnostic and therapeutic radiopharmaceuticals, which will enable early and accurate diagnosis and treatment of disease leading to better patient outcomes.
For more information, visit jubilantradiopharma.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding Navidea’s ability to enter into the ELDA on terms acceptable to Navidea, if at all, potential benefits to Navidea under the ELDA, Jubilant’s ability to act as an effective commercial and distribution partner, and Jubilant’s expected expansion into the radio-diagnostics market. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our ability to negotiate and enter into the ELDA on acceptable terms, if at all; Jubilant’s ability to act as a successful commercial distribution partner; our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at https://www.sec.gov or at https://ir.navidea.com.
Investors are urged to consider statements that include the words "will,” "may,” "could,” "should,” "plan,” "continue,” "designed,” "goal,” "forecast,” "future,” "believe,” "intend,” "expect,” "anticipate,” "estimate,” "project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Navidea is not responsible for the contents of third-party websites.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005208/en/
The Democratic candidate Joe Biden is on the brink of White House on projected wins in Michigan and Wisconsin Yellow metal prices inched higher as the U.S. dollar heads in the opposite direction A break above $1,930 will pave the way for a test of $1,975, especially if dollar weakness persists Gold prices soared nearly 1% on Thursday after the U.S. dollar fell on new updates from the U.S. elections race that signal the Democratic candidate Joe Biden is on the brink of White House. Fundamental analysis: Dollar slips as Biden makes a big step towards presidency Spot gold prices yesterday dropped on the uncertainty related to U.S. presidential elections. The dollar headed in the opposite direction. Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today. “The knee-jerk climb in the dollar index heaped downward pressure on the precious metal,” said Han Tan, an analyst at FXTM. “With the Blue Wave’s path now obfuscated, a divided Senate threatens to slow any passage of fresh U.S. fiscal stimulus. Such prospects are dampening gold’s ability to push higher for the time being.” President Trump triumphed in the swing states of Florida, Ohio